Pfizer's CEO discussed the extensive due diligence the company has conducted on the 3SBio PD-1xVEGF deal. | Pfizer's CEO ...

Despite a recent rebuff from an FDA advisory committee, the first treatment for a specific and underserved cohort of U.S. | ...

Amid the threat of pharmaceutical tariffs from President Donald Trump, recent months have seen multibillion-dollar U.S.

For the second time in nine months, a Delaware judge has sided (PDF) with Syntimmune shareholders over AstraZeneca, granting ...

Cobenfy, the novel antipsychotic drug that Bristol Myers Squibb obtained from a $14 billion acquisition, could have a problem ...

Sprout Pharmaceuticals is once again under fire from the FDA’s Office of Prescription Drug Promotion (OPDP). | Sprout ...

With what Insmed calls an "outstanding" phase 2 win for its treprostinil palmitil inhalation powder (TPIP) in patients with ...

GSK is putting the finishing touches on its case for antibody-drug conjugate Blenrep with a key progression-free survival ...

Havas Media Network has set up an advertising marketplace to help companies reach patients who are cut off from healthcare by ...

Right after Robert F. Kennedy Jr. secured confirmation as U.S. | The Department of Health and Human Services has removed all ...

With great power comes great responsibility, and Insulet, accordingly, is using its influence in the diabetes management ...

Despite an outcry from the biopharmaceutical industry, the U.K. government has kept the rebate rate under a national ...